HORSHAM, Pa. and KENILWORTH, N.J., Oct. 6 (HSMN NewsFeed) — Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP ) announced today that the European Commission has approved SIMPONI(TM) (golimumab) as a once-monthly, subcutaneous therap…
Biopharmaceuticals, Regulatory
Schering-Plough, Centocor Ortho Biotech, SIMPONI, golimumab

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector”
Leave a Comment